Abstract—
The development of Selank based on the natural regulatory peptide tuftsin allowed combining the native bioactivity of the molecule with the design engineering of certain physiological functions. Based on a summary of the experimental and clinical data, a comparative analysis of the structural and functional regularities of the effects of Selank and its fragments was performed. The qualitative and quantitative characteristics of correctional processes (anxiolytic, cognitive, immunostimulatory, anti-ulcer, etc.), triggered by the peptide drug and its analogues, are summarized into a single scheme. It is assumed that the Selank effect on the network of cascade processes of peptides and mediators is carried out through enkephalin, the key player of this system.
Similar content being viewed by others
REFERENCES
Andreeva, L.A., Nagaev, I.Yu., Mezentseva, M.V., Shapoval, I.M., Podchernyaeva, R.Ya., Shcherbenko, V.E., Potapova, L.A., Russu, L.I., Ershov, F.I., and Myasoedov, N.F., Antiviral properties of structural fragments of the peptide Selank, Dokl. Biol. Sci., 2010, vol. 431, pp. 79–82.
Andreeva, L.A., Myasoedov, N.F., Lyapina, L.A., Grigor’eva, M.E., Obergan, T.Yu., and Shubina, T.A., Effect of the Pro–Gly–Pro peptide on hemostasis and lipid metabolism in rats with hypercholesterolemia, Dokl. Biol. Sci., 2013, vol. 453, pp. 333–335.
Ershov, F.I., Uchakin, P.N., Uchakina, O.N., Mezentseva, M.V., Alekseeva, L.A., and Myasoedov, N.F., Activity of the immunomodulator Selank in experimental influenza infection, Vopr. Virusol., 2009, vol. 5, pp. 19–24.
Kolomin, T.A., Shadrina, M.I., Agniullin, Ya.V., Shram, S.I., Slominskii, P.A., Limborskaya, S.A., and Myasoedov, N.F., Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide Selank, Dokl. Biochem. Biophys., 2010, vol. 430, pp. 5–6.
Kolomin, T.A., Shadrina, M.I., Slominsky, P.A., Limborska, S.A., and Myasoedov, N.F., Changes in expression of the genes for chemokines, cytokines, and their receptors in response to Selank and its fragments, Russ. J. Genet., 2011a, vol. 47, no. 5, pp. 629–631.
Kolomin, T., Shadrina, M., Andreeva, L., Slominsky, P., Limborska, S., and Myasoedov, N., Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank, Regul. Peptides, 2011b, vol. 170, pp. 18–23.
Koroleva, S.V. and Myasoedov, N.F., Dynamic hierarchy of regulatory peptides. The structure of the inductive relationships of regulators as a target for therapeutic interventions, Usp. Fiziol. Nauk, 2012, vol. 43, no. 3, pp. 38–47.
Koroleva, S.V., Nikolaeva, A.A., and Ashmarin, I.P., Types of bioinformatic programs in the continuum of regulatory peptides and non-peptide mediators. Traits of interaction of dopamine and serotonin systems, Neurochem. J., 2012, vol. 6, no. 2, pp. 132–143.
Kost, N.V., Sokolov, O.Yu., Gabaeva, N.V., Grivennikov, I.A., Andreeva, L.A, Myasoedov, N.F., and Zozulya, A.A., Semax and Selank inhibit the enkephalin-degrading enzymes of human serum, Russ. J. Bioorg. Chem., 2001, vol. 27, no. 3, pp. 156–159.
Kozlovskaya, M.M., Seredenin, S.B., Kozlovskii, I.I., Val’dman, E.A., Andreeva, L.A., and Myasoedov, N.F., Comparative study of the effect of tuftsin fragments on the indices of passive avoidance response, Khim.-Farm. Zh., 2001, vol. 35, no. 3, pp. 3–5.
Kozlovskaya, M.M., Seredenin, S.B., Kozlovskii, I.I., Val’dman, E.A., Andreeva, L.A., and Myasoedov, N.F., Comparative analysis of the structural and functional characteristics of the peptide Selank, Psikhofarmakol. Biol. Narkol., 2002, vol. 2, nos. 1–2, pp. 203–210.
Lyapina, L.A., Myasoedov, N.F., Andreeva, L.A., Ul’yanov, A.M., Obergan, T.Yu., Shubina, T.A., and Pastorova, V.E., Fibrinolytic and hypoglycemic effects of the Pro–Gly–Pro–Leu peptide during development of insulin-dependent diabetes in rats, Biol. Bull. (Moscow), 2010, vol. 37, no. 3, pp. 316–320.
Lyapina, L.A., Myasoedov, N.F., Grigor’eva, M.E., Shubina, T.A., and Andreeva, L.A., The modern concept of the regulatory role of peptides of the glyproline family in the correction of hemostasis system function during development of diabetes mellitus, Biol. Bull. (Moscow), 2013, vol. 40, no. 4, pp. 386–393.
Meshavkin, V.K., Kost, N.V., Sokolov, O.Yu., Zolotarev, Yu.A., Myasoedov, N.F., and Zozulya, A.A., Naloxone-blocked depriming effect of anxiolytic Selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system, Bull. Exp. Biol. Med., 2006, vol. 142, no. 5, pp. 598–600.
Pavlov, T.S., Samonina, G.E., Andreeva, L.A., Myasoedov, N.F., and Ashmarin, I.P., A new property of the synthetic anxiolytic Selank and its derivatives, Dokl. Biol. Sci., 2004, vol. 397, pp. 281–283.
Sangadzhieva, A.D., Bakaeva, Z.V., Samonina, G.E., Mezentseva, M.V., Andreeva, L.A., and Myasoedov, N.F., Effect of glyprolines PGP and N-acetyl-PGP on the expression of cytokine genes during stress- and acetate-induced ulceration, Moscow Univ. Biol. Sci. Bull., 2014, vol. 69, no. 4, pp. 141–146.
Uchakina, O.N., Uchakin, P.N., Myasoedov, N.F., Andreeva, L.A., Shcherbenko, V.E., Mezentseva, M.V., Gabaeva, M.V., Sokolov, O.Yu., Zozulya, A.A., and Ershov, F.I., Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders, Zh. Nevrol. Psikhiatr., 2008, vol. 108, no. 5, pp. 71–75.
Ul’yanov, A.M., Lyapina, L.A., Obergan, T.Yu., Shubina, T.A., Pastorova, V.E., Andreeva, L.A., Myasoedov, N.F., and Ashmarin, I.P., Antidiabetogenic action of Pro–Gly–Arg and Pro–Gly–Pro–Arg peptides after their intranasal chronic administration to animals, Biol. Bull. (Moscow), 2009, vol. 36, no. 6, pp. 630–633.
V’yunova, T.V., Andreeva, L.A., Shevchenko, K.V., Shevchenko, V.P., and Myasoedov, N.F., Peptide regulation of specific ligand–receptor interactions of GABA with the plasma membranes of nerve cells, Neurochem. J., 2014, vol. 8, no. 4, pp. 259–264.
Zozulya, A.A., Kost, N.V., Sokolov, O.Yu., Gabaeva, N.V., Grivennikov, I.A., Andreeva, L.A., Zolotarev, Yu.A., Ivanov, S.V., Andryushchenko, L.N., Myasoedov, N.F., and Smulevich, A.B., The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity, Bull. Exp. Biol. Med., 2001, vol. 131, no. 4, pp. 315–317.
Zozulya, A.A., Neznamov, G.G., Syunyakov, T.S., Kost, N.V., Gabaeva, M.V., Sokolov, O.Yu., Serebryakova, E.V., Siranchieva, O.A., Andryushchenko, A.V., Telesheva, E.S., Syunyakov, S.A., Smulevich, A.V., Myasoedov, N.F., and Seredenin, S.B., The efficacy and possible mechanisms of action of the new peptide anxiolytic Selank in the treatment of generalized anxiety disorder and neurasthenia, Zh. Nevrol. Psikhiatr., 2008, vol. 4, pp. 38–48.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated by D. Novikova
Rights and permissions
About this article
Cite this article
Koroleva, S.V., Mjasoedov, N.F. Physiological Effects of Selank and Its Fragments. Biol Bull Russ Acad Sci 46, 407–414 (2019). https://doi.org/10.1134/S1062359019040071
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1062359019040071